Anil K Chaturvedi1, Hormuzd A Katki1, Stephanie A Kovalchik1, Martin Tammemagi1, Christine D Berg1, Neil E Caporaso1, Tom L Riley1, Mary Korch1, Gerard A Silvestri1. 1. Divisions of Cancer Epidemiology and Genetics (S.A.K., N.E.C., A.K.C., H.A.K.) and Cancer Prevention (C.D.B.), National Cancer Institute, National Institutes of Health, and Information Management Services (T.L.R., M.K.) - all in Rockville, MD; the Department of Community Health Sciences, Brock University, St. Catharines, ON, Canada (M.T.); and the Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston (G.A.S.).
Abstract
BACKGROUND: In the National Lung Screening Trial (NLST), screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung-cancer mortality among participants between the ages of 55 and 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since quitting. It is not known whether the benefits and potential harms of such screening vary according to lung-cancer risk. METHODS: We assessed the variation in efficacy, the number of false positive results, and the number of lung-cancer deaths prevented among 26,604 participants in the NLST who underwent low-dose CT screening, as compared with the 26,554 participants who underwentchest radiography, according to the quintile of 5-year risk of lung-cancer death (ranging from 0.15 to 0.55% in the lowest-risk group [quintile 1] to more than 2.00% in the highest-risk group [quintile 5]). RESULTS: The number of lung-cancer deaths per 10,000 person-years that were prevented in the CT-screening group, as compared with the radiography group, increased according to risk quintile (0.2 in quintile 1, 3.5 in quintile 2, 5.1 in quintile 3, 11.0 in quintile 4, and 12.0 in quintile 5; P=0.01 for trend). Across risk quintiles, there were significant decreasing trends in the number of participants with false positive results per screening-prevented lung-cancer death (1648 in quintile 1, 181 in quintile 2, 147 in quintile 3, 64 in quintile 4, and 65 in quintile 5). The 60% of participants at highest risk for lung-cancer death (quintiles 3 through 5) accounted for 88% of the screening-prevented lung-cancer deaths and for 64% of participants with false positive results. The 20% of participants at lowest risk (quintile 1) accounted for only 1% of prevented lung-cancer deaths. CONCLUSIONS: Screening with low-dose CT prevented the greatest number of deaths from lung cancer among participants who were at highest risk and prevented very few deaths among those at lowest risk. These findings provide empirical support for risk-based targeting of smokers for such screening. (Funded by the National Cancer Institute.).
RCT Entities:
BACKGROUND: In the National Lung Screening Trial (NLST), screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung-cancer mortality among participants between the ages of 55 and 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since quitting. It is not known whether the benefits and potential harms of such screening vary according to lung-cancer risk. METHODS: We assessed the variation in efficacy, the number of false positive results, and the number of lung-cancer deaths prevented among 26,604 participants in the NLST who underwent low-dose CT screening, as compared with the 26,554 participants who underwent chest radiography, according to the quintile of 5-year risk of lung-cancer death (ranging from 0.15 to 0.55% in the lowest-risk group [quintile 1] to more than 2.00% in the highest-risk group [quintile 5]). RESULTS: The number of lung-cancer deaths per 10,000 person-years that were prevented in the CT-screening group, as compared with the radiography group, increased according to risk quintile (0.2 in quintile 1, 3.5 in quintile 2, 5.1 in quintile 3, 11.0 in quintile 4, and 12.0 in quintile 5; P=0.01 for trend). Across risk quintiles, there were significant decreasing trends in the number of participants with false positive results per screening-prevented lung-cancer death (1648 in quintile 1, 181 in quintile 2, 147 in quintile 3, 64 in quintile 4, and 65 in quintile 5). The 60% of participants at highest risk for lung-cancer death (quintiles 3 through 5) accounted for 88% of the screening-prevented lung-cancer deaths and for 64% of participants with false positive results. The 20% of participants at lowest risk (quintile 1) accounted for only 1% of prevented lung-cancer deaths. CONCLUSIONS: Screening with low-dose CT prevented the greatest number of deaths from lung cancer among participants who were at highest risk and prevented very few deaths among those at lowest risk. These findings provide empirical support for risk-based targeting of smokers for such screening. (Funded by the National Cancer Institute.).
Authors: Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel Journal: J Natl Cancer Inst Date: 2007-05-02 Impact factor: 13.506
Authors: Martin M Oken; Pamela M Marcus; Ping Hu; Thomas M Beck; William Hocking; Paul A Kvale; Jill Cordes; Thomas L Riley; Stephen D Winslow; Steven Peace; David L Levin; Philip C Prorok; John K Gohagan Journal: J Natl Cancer Inst Date: 2005-12-21 Impact factor: 13.506
Authors: Peter B Bach; Michael W Kattan; Mark D Thornquist; Mark G Kris; Ramsey C Tate; Matt J Barnett; Lillian J Hsieh; Colin B Begg Journal: J Natl Cancer Inst Date: 2003-03-19 Impact factor: 13.506
Authors: Richard Wender; Elizabeth T H Fontham; Ermilo Barrera; Graham A Colditz; Timothy R Church; David S Ettinger; Ruth Etzioni; Christopher R Flowers; G Scott Gazelle; Douglas K Kelsey; Samuel J LaMonte; James S Michaelson; Kevin C Oeffinger; Ya-Chen Tina Shih; Daniel C Sullivan; William Travis; Louise Walter; Andrew M D Wolf; Otis W Brawley; Robert A Smith Journal: CA Cancer J Clin Date: 2013-01-11 Impact factor: 508.702
Authors: Paul K J Han; Christine W Duarte; Susannah Daggett; Andrea Siewers; Bill Killam; Kahsi A Smith; Andrew N Freedman Journal: Patient Educ Couns Date: 2015-07-19
Authors: Pablo Sanchez-Salcedo; David O Wilson; Juan P de-Torres; Joel L Weissfeld; Juan Berto; Arantzazu Campo; Ana B Alcaide; Jesús Pueyo; Gorka Bastarrika; Luis M Seijo; Maria J Pajares; Ruben Pio; Luis M Montuenga; Javier J Zulueta Journal: Am J Respir Crit Care Med Date: 2015-04-15 Impact factor: 21.405
Authors: Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405
Authors: Benjamin S Wessler; Lana Lai Yh; Whitney Kramer; Michael Cangelosi; Gowri Raman; Jennifer S Lutz; David M Kent Journal: Circ Cardiovasc Qual Outcomes Date: 2015-07-07